Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12

Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek

. 2010 ; 28 (4) : 445-453.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12026045

Grantová podpora
NS9812 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK ProQuest Central od 1997-01-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Nursing & Allied Health Database (ProQuest) od 1997-01-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-01-01 do Před 1 rokem
Family Health Database (ProQuest) od 1997-01-01 do 2017-12-31

In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12026045
003      
CZ-PrNML
005      
20150105154902.0
007      
ta
008      
120817s2010 xxu f 000 0#eng||
009      
AR
024    7_
$a 10.1007/s10637-009-9270-4 $2 doi
035    __
$a (PubMed)19499188
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Roubalová, Eva $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic; Department of Biology and Wildlife Diseases, Faculty of Veterinary Hygiene and Ecology, University of Veterinary and Pharmaceutical Sciences, Brno, Czech Republic
245    14
$a The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12 / $c Eva Roubalová, Veronika Kvardová, Roman Hrstka, Šárka Bořilová, Eva Michalová, Lenka Dubská, Petr Müller, Petr Sova, Bořivoj Vojtěšek
520    9_
$a In this study, we characterized the effects of LA-12 on tumor cell lines possessing wild type p53 and on p53-deficient/mutant cell lines and the results were compared to those obtained using cisplatin. We have determined changes of p53 levels, of its transcriptional activity, of its posttranscriptional modifications and the effect of the treatment on the cell cycle, on the induction of apoptosis and on gene expression. LA-12 induces weak accumulation of both transcriptionally active p53 tumor suppressor and of p21(WAF1/CIP1) protein. LA-12 and cisplatin also significantly differ in their effects on apoptosis and cell cycle and on gene expression spectra in studied cell lines. LA-12 induces higher apoptosis levels in comparison with those induced by cisplatin, especially in p53-deficient H1299 cells and in MCF-7DD cells with transcriptionally inactive p53. We suggest that LA-12-mediated apoptosis is not fully dependent on p53. This confirms the therapeutic potential of LA-12 as a more potent cytostatic agent for both tumor cells expressing wild type p53 and for p53-deficient or mutant cells.
650    _2
$a amantadin $x analogy a deriváty $x farmakologie $7 D000547
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a proteiny regulující apoptózu $x metabolismus $7 D051017
650    _2
$a buněčný cyklus $x účinky léků $7 D002453
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a cisplatina $x farmakologie $7 D002945
650    _2
$a inhibitor p21 cyklin-dependentní kinasy $x metabolismus $7 D050759
650    _2
$a regulace genové exprese u nádorů $x účinky léků $7 D015972
650    _2
$a geny p53 $7 D016158
650    _2
$a lidé $7 D006801
650    _2
$a mutace $7 D009154
650    _2
$a organoplatinové sloučeniny $x farmakologie $7 D009944
650    _2
$a nádorový supresorový protein p53 $x genetika $x metabolismus $7 D016159
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Kvardová, Veronika $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Hrstka, Roman $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Bořilová, Šárka $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Michalová, Eva $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Dubská, Lenka $u Department of Laoratory Medicine, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Müller, Petr $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Sova, Petr $u Research and Development, PLIVA-Lachema a.s., Brno, Czech Republic
700    1_
$a Vojtěšek, Bořivoj $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
773    0_
$w MED00008129 $t Investigational new drugs $x 1573-0646 $g Roč. 28, č. 4 (2010), s. 445-453
856    41
$u https://pubmed.ncbi.nlm.nih.gov/19499188 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120817 $b ABA008
991    __
$a 20150105155038 $b ABA008
999    __
$a ok $b bmc $g 948087 $s 783391
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2010 $b 28 $c 4 $d 445-453 $i 1573-0646 $m Investigational new drugs $n Invest New Drugs $x MED00008129
GRA    __
$a NS9812 $p MZ0
LZP    __
$a Pubmed-20120817/10/03

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...